KENIL HEALTHCARE's Artridon Glucosamine Recalled Over CGMP Failures, Highlighting India Manufacturing Risks
KENIL HEALTHCARE PRIVATE LIMITED initiated a Class II recall (D-0421-2025) for 9,984 tubes of Artridon Glucosamine, a topical analgesic containing menthol and methyl salicylate, due to Current Good Manufacturing Practice (CGMP) deviations at its India facility. This terminated recall highlights persistent quality control risks in overseas manufacturing, necessitating rigorous supplier qualification and ongoing vigilance for procurement and regulatory teams sourcing similar active pharmaceutical ingredients and finished products.
FDA Mandates Class II Recall for KENIL HEALTHCARE's Artridon Glucosamine Due to CGMP Failures
KENIL HEALTHCARE PRIVATE LIMITED, based in India, initiated a Class II recall (D-0421-2025) on April 24, 2025, for its Artridon Glucosamine topical analgesic. This product, containing menthol 2% and methyl salicylate 15%, is marketed for arthritis joint pain relief under NDC 55758-030-05 and UPC 810096771513. The recall, which involved 9,984 tubes from Lot SP25A with an expiration date of September 30, 2026, was triggered by identified Current Good Manufacturing Practice (CGMP) deviations. For procurement and regulatory directors, this event underscores the critical importance of stringent quality assurance protocols and continuous oversight of contract manufacturing organizations (CMOs). A Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote, still carries significant commercial and reputational risks. While the recall was terminated on February 19, 2026, signifying the completion of product removal, the underlying CGMP issues demand a thorough re-evaluation of supplier quality systems to prevent future recurrences and ensure supply chain integrity.
Commercial Impact and Supply Chain Vulnerabilities for Topical Analgesic Formulations
The recall of Artridon Glucosamine, distributed by Pharmadel LLC in New Castle, DE, and affecting markets in Delaware (DE) and North Carolina (NC), highlights specific vulnerabilities within the supply chain for topical analgesics. The withdrawal of 9,984 tubes from these key distribution channels represents a tangible disruption for retailers and healthcare providers relying on these products. For business development executives and supply chain VPs, this incident necessitates an immediate assessment of their exposure to similar menthol and methyl salicylate-based formulations, especially those sourced from overseas manufacturers. The logistical complexities and costs associated with managing a product recall, including inventory retrieval and communication with customers, can significantly impact profitability and market share. This event serves as a critical reminder to diversify sourcing strategies and implement robust contingency plans to mitigate the financial and operational fallout from unforeseen quality issues, ensuring continuity of supply for essential OTC medications.
Heightened Scrutiny on Indian Pharmaceutical Manufacturing and Supplier Qualification Imperatives
The fact that Artridon Glucosamine was 'Made in India' by KENIL HEALTHCARE PRIVATE LIMITED, with its facility located in Ta. Kadi, District Mehsana, places this recall within a broader context of increased FDA scrutiny on pharmaceutical manufacturing in the region. This trend is further evidenced by parallel events such as Essential Wellness Pharma's Class II recall for Progesterone Injection due to sterility assurance failures. For procurement directors and regulatory affairs heads, this reinforces the imperative for rigorous, independent supplier qualification and audit programs for all contract manufacturing partners in India. Relying solely on a supplier's self-attestation of compliance is an unacceptable risk. Companies must conduct comprehensive, on-site audits to verify CGMP adherence, assess quality management systems, and ensure data integrity. Failure to proactively manage these risks exposes businesses to potential import alerts, costly recalls, and significant reputational damage, directly impacting market access and long-term commercial viability in the global chemical and life sciences industry.
Recall Termination and Ongoing Due Diligence for Procurement Teams
The 'Terminated' status of recall D-0421-2025 as of February 19, 2026, indicates that the FDA has verified KENIL HEALTHCARE PRIVATE LIMITED has successfully completed all required actions to remove or correct the affected product from the market. However, for senior decision-makers, this termination does not diminish the importance of addressing the underlying CGMP deviations that led to the recall. Regulatory affairs heads must ensure that comprehensive corrective and preventive actions (CAPAs) have been implemented and validated by the manufacturer. Procurement teams should not only review this specific incident but also evaluate all other products sourced from KENIL HEALTHCARE or other facilities in the Ta. Kadi, District Mehsana region of India. Future sourcing decisions must incorporate enhanced risk assessments, including detailed reviews of a supplier's post-recall remediation efforts and ongoing compliance monitoring. Proactive engagement and verification of robust quality systems are paramount to safeguarding supply continuity and maintaining regulatory compliance.